In the anti-PD-1 and mixed therapy cohorts, PD-L1 positivity on pre-treatment tumor cells was correlated with clinical benefit in 9/14 analyses, PFS in 2/5 analyses and OS in 4/8 analyses, although 64% of the studies were estimated as having a high risk of bias. This evidence concerns the gene CD274 and neoplasm.